PART I . Overview We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) enabling less frequent and more convenient self-administered subcutaneous (S.C.) injections suitable for...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001690585-26-000006 | EDGAR | 93K words |
| 2025-03-11 | 2024-12-31 | 0000950170-25-037131 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034681 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009331 | EDGAR | — |
| 2022-03-08 | 2021-12-31 | 0001193125-22-068759 | EDGAR | — |
| 2021-03-03 | 2020-12-31 | 0001193125-21-066707 | EDGAR | — |
| 2020-03-03 | 2019-12-31 | 0001193125-20-059835 | EDGAR | — |
| 2019-03-19 | 2018-12-31 | 0001193125-19-078948 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-266920 | EDGAR | 28K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105030 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069226 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123285 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093948 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057022 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062070 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037605 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-022192 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021603 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001193125-22-211881 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001193125-22-151014 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001690585-26-000010 | EDGAR | 11K words |
| 2026-03-12 | 0001193125-26-103053 | EDGAR | — |
| 2026-03-09 | 0001193125-26-097555 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009898 | EDGAR | — |
| 2025-11-05 | 0001193125-25-266867 | EDGAR | — |
| 2025-11-03 | 0001193125-25-262188 | EDGAR | — |
| 2025-10-16 | 0001193125-25-240858 | EDGAR | — |
| 2025-09-11 | 0001193125-25-200715 | EDGAR | — |
| 2025-09-08 | 0001193125-25-197751 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105002 | EDGAR | — |
146 total filings indexed. 116 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001690585 |
| Ticker | DNTH |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.dianthustx.com |
| Listed | 2023-09-12 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report